Regeneron reports third quarter 2022 financial and operating results

Third quarter 2022 revenues decreased 15% to $2.94 billion versus third quarter 2021; excluding regen-cov ® (a)(b), revenues increased 11% third quarter 2022 eylea® u.s. net sales increased 11% versus third quarter 2021 to a record $1.63 billion third quarter 2022 dupixent® global net sales(c)(recorded by sanofi) increased 40% to $2.33 billion versus third quarter 2021 third quarter 2022 gaap diluted eps of $11.66; non-gaap diluted eps(a) of $11.14 positive results reported in aflibercept 8 mg pivotal trials for diabetic macular edema (dme) and neovascular age-related macular degeneration (wet amd) eylea granted additional six months of pediatric exclusivity by the fda fda approved dupixent for prurigo nodularis inmazeb® won 2022 prix galien usa "best biotechnology product" award tarrytown, n.y., nov. 3, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced financial results for the third quarter of 2022 and provided a business update.
REGN Ratings Summary
REGN Quant Ranking